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Natural killer T  cells carrying a highly conserved, semi-invariant T  cell receptor (TCR) 
[invariant natural killer T (iNKT) cells] are a subset of unconventional T lymphocytes that 
recognize glycolipids presented by CD1d molecules. Although CD1d is expressed on 
a variety of hematopoietic and non-hematopoietic cells, dendritic cells (DCs) are key 
presenters of glycolipid antigen in vivo. When stimulated through their TCR, iNKT cells 
rapidly secrete copious amounts of cytokines and induce maturation of DCs, thereby 
facilitating coordinated stimulation of innate and adaptive immune responses. The 
bidirectional crosstalk between DCs and iNKT cells determines the functional outcome 
of iNKT cell-targeted responses and iNKT cell agonists are used and currently being 
evaluated as adjuvants to enhance the efficacy of antitumor immunotherapy. This review 
illustrates mechanistic underpinnings of reciprocal DCs and iNKT cell interactions and 
discusses how those can be harnessed for cancer therapy.
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NATURAL KiLLeR T CeLLS (NKT CeLLS)
Natural killer T cells belong to the group of innate-like T  lymphocytes and represent an impor-
tant link between the innate and the adaptive immune response. They can be activated in both 
antigen-dependent and independent manners, secrete large amounts of cytokines upon activation, 
and exhibit remarkable functional plasticity with both pro-inflammatory and immunoregulatory 
characteristics (1, 2). Depending on their T  cell receptor (TCR), CD1d-restricted NKT  cells are 
subdivided into type I or invariant NKT (iNKT) cells, and type II or diverse NKT (dNKT) cells. 
Herein, we will focus on the unique iNKT cell subset, which expresses a semi-invariant TCR and we 
refer the reader to excellent reviews on type II NKT cells elsewhere (3, 4).
In 1986 and 1987, respectively, three key discoveries facilitated the identification of this innate-
like T  cell subset. Two groups independently described a Vβ8-overexpressing, double-negative 
thymocyte subset in mice, while a third research team cloned an invariant TCR Vα14-Jα18 rear-
rangement from a set of murine suppressor T cell hybridomas (5–7). It was not until 10 years later 
that the ligands, which these peculiar cells recognize, were identified (8).
Type I NKT cells are characterized by the expression of a semi-invariant TCR (Vα14Jα18 paired 
with Vβ8, Vβ7, or Vβ2 in mice and Vα24Jα18/Vβ11 in humans) (3, 9). Interestingly, the Vα14 
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TCR is exclusively used by iNKT cells but not by conventional 
T cells (10). Furthermore, iNKT cell subsets bear morphological 
markers on their surface that were believed to be characteristic 
for natural killer (NK) cells like NKG2D (11), KLRG (12), IL-12 
receptor (13), or NK1.1 (CD161) (8, 14–16). However, although 
expression of these molecules may characterize some NKT cell 
subsets, other subsets do not share these NK  cell markers. 
Therefore, the more stringent characteristic of NKT cells appears 
to be their CD1d restriction (1).
Unlike conventional CD4+ or CD8+ T cells, iNKT cells recog-
nize antigenic glycolipids presented via the monomorphic MHC 
class I-like molecule CD1d (17, 18). iNKT  cell responses have 
proven to be highly conserved between humans and mice. They 
enhance the activation of innate immune cells, such as dendritic 
cells (DCs) and NK cells, and shape immune responses in concert 
with other lymphocytes, such as B cells. Thereby, iNKT cells not 
only act as an amplification relay but bridge innate and adaptive 
immunity (19–22). The frequencies of iNKT  cells among total 
lymphocytes differ greatly between tissues and the possibility 
of detecting these unconventional T cells has greatly improved 
by the introduction of lipid-loaded CD1d-tetramers (15, 16). In 
mice, iNKT cells are most abundant in the liver (10–30%) and 
the spleen (0.5–1.5%) with lower frequencies found in thymus, 
blood, bone marrow (all 0.2–0.5%), and lymph nodes (0.1–0.2%). 
In humans, substantial interindividual variability is observed. 
However, high iNKT  cell frequencies are detected in the liver 
(1%), omentum (10%), the adipose tissue (in which iNKT  cell 
frequencies vary between 0.5 and 1% of total CD3+ cells) (23), 
and in healthy donors iNKT cells represent 0.01–0.5% of PBMCs 
(24, 25). The iNKT cell subset develops in the thymus, emerges 
from the same progenitor pool as conventional T cells, and under-
goes somatic recombination and thymic selection. Rather than via 
thymic epithelial cells, iNKT cells are positively selected through 
interaction with double-positive thymocytes that CD1d-present 
endogenous ligands, leading to an unusually strong TCR signal. 
The directing of iNKT cell precursors toward a particular subset 
lineage may involve specific endogenous selecting lipid antigens 
(19, 26, 27). The majority of human thymic iNKT cells egresses 
during early fetal development and CD4+CD8− iNKT  cells are 
already present at birth, whereas murine iNKT cells only emerge 
during the first postnatal week (25, 28, 29). Distinct human 
iNKT cell subsets include CD4+/CD8−, CD4−/CD8−, and CD4−/
CD8+ whereas in mouse CD4+/CD8− and CD4−/CD8− subsets 
prevail (25).
iNKT CeLL HeTeROGeNeiTY  
AND eFFeCTOR FUNCTiONS
Initially believed to be a rather rigid and homogenous cell 
population that merely acts upon TCR stimulation, it became 
recently clear that based on their respective transcriptional pro-
grams, distinct iNKT cell subsets with designated functional prop-
erties exist and that iNKT cells may balance immune homeostasis 
via their steady-state activity. TCR-induced transcription factors 
Egr2 and Egr1 lead to transcription of PLZF, the key transcrip-
tional factor during the development of iNKT cells (30). In fact, 
although only a subset of fully matured iNKT cells are positive 
for PLZF, the majority of iNKT cells expresses this transcription 
factor at one point during development (31–34). Depending on 
the subsequent transcriptional program, thymic CD24hi/CD69+ 
iNKT  cell precursors diverge into distinct sublineages (35). 
TH1 iNKT cells (NKT1) express T-bet and Bhlhe40 and mainly 
release IFNγ upon TCR ligation. TH2 iNKT  cells (NKT2) pre-
dominantly express GATA3 and PLZF and release IL-4 and IL-13 
already in steady state. IL-17-producing iNKT17 express RORγt, 
a subset of Bcl-6-dependent, CXCR5- and PD1-expressing 
iNKT follicular helper cells secrete IL-21, thereby shaping 
B  cell responses. IL-10-producing immunoregulatory NKT10 
are FOXP3-negative but positive for the transcription factor 
E4BP4 (20, 27, 36–38). Recently, a KLRG-expressing subset of 
iNKT cells has been described, which shows an effector-memory-
like phenotype and is able to mount stronger secondary responses 
to cognate antigen (12).
Invariant NKT cells can be activated either upon stimulation 
of their TCR by CD1d-presented glycolipid antigens, or in a 
TCR-independent manner (e.g., by cytokines) (39, 40). Upon 
activation, iNKT cells readily proliferate and undergo significant 
remodeling of their surface expression patterns with regards to 
several markers, such as NK1.1 and the semi-invariant TCR (41).
Although iNKT cells have adaptive characteristics, they exist 
in a preactivated memory-like effector state primed to release 
large amounts of immunomodulatory cytokines (including 
IFNγ, IL-4, IL-13, IL-17, GM-CSF, and TNF-α) not only upon 
engagement of their TCR but also in response to innate signals 
(13). One of their key features is the cytokine-mediated trans-
activation of other innate and innate-like immune cell subsets, 
thereby amplifying initial responses (19, 42–45). In addition, 
iNKT cells may also provide both antigen-specific cognate and 
non-cognate help for B cells (20, 46, 47) and in turn can be acti-
vated by B  cells (48, 49). Interestingly, unlike the non-cognate 
iNKT  cell–B  cell interactions, antigen-specific iNKT  cell help 
induces a more innate-biased B cell response, which is charac-
terized by a discontinuous germinal center B cell expansion and 
rapid initial proliferation of IL-10-producing B cells, but fails to 
induce humoral memory (50).
A key difference between iNKT cells and conventional T cells 
are the kinetics of their responses, which in case of iNKT cells 
occur already within hours after engagement, as opposed to 
several days in the case of conventional T cells (1, 51). In line with 
this, iNKT cells have been reported to carry preformed mRNA 
of cytokines in their cytoplasm, which enables them to rapidly 
release large quantities of these effector molecules upon TCR liga-
tion (52, 53). The translational regulation of preformed cytokine 
mRNA has been shown to be dependent on p38 MAPK (54).
Aside from rapidly releasing numerous immunomodulatory 
cytokines, iNKT  cells also have immediate cytotoxic capacity, 
which correlates with the amount of surface CD1d on the target 
cell (55). While reports in patients suffering from acute myeloid 
leukemia (AML) and juvenile myelomonocytic leukemia describe 
(analogous to NK cell-mediated cytotoxicity) predominant usage 
of the perforin/granzyme B pathway in executing cytotoxicity, 
other reports in C57BL/6 mice ascribe a higher importance to 
Fas/FasL interaction (55). In addition to exerting direct effector 
functions, it becomes more and more apparent that iNKT may 
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shape immune responses indirectly through crosstalk with other 
immune subsets.
Myeloid-derived suppressor cells (MDSCs) are a unique Gr1+ 
population of activated myeloid cells that retain an immature 
phenotype and are functionally able to dampen adaptive immune 
responses during malignancies and infection (56). De Santo et al. 
described an intriguing mechanism through which iNKT  cells 
reverse the suppressive properties of MDSCs during influenza A 
virus (IAV) infection in a CD1d- and CD40:CD40L-dependent 
manner (57). While infection of both CD1d−/− and Jα18−/− mice 
with the IAV strain A/Puerto Rico/8/34 (PR8) lead to a more 
severe phenotype and a greater expansion of CD1d- and CD40-
expressing MDSCs in the lungs of Jα18−/− and CD1d−/− mice as 
compared to PR8-infected wild-type mice, only adoptive transfer 
of iNKT cells into Jα18−/− mice ameliorated the disease course 
and reduced MDSC numbers whereas CD1d−/− mice remained 
hypersusceptible and depicted unchanged numbers of MDSCs. 
MDSCs isolated from the lungs of PR8-infected Jα18−/− mice 
depicted a stronger suppressive activity as those from wild-type 
mice. Pulsing MDSCs with αGalCer or TLR agonists (for TLRs 3, 
7/8, and 9) in the presence of iNKT cells reduced suppressive activ-
ity of MDSCs. The results of this study suggest that TLR-mediated 
upregulation of (yet to be defined) endogenous iNKT cell ligands 
contribute to the iNKT  cell-mediated modulation of MDSC 
suppressive activity during IAV infection. Accordingly, immu-
nosuppressive properties of MDSCs isolated from IAV-infected 
patients could be reversed by iNKT cells (57). Likewise, it was 
shown that MDSCs pulsed with tumor-associated antigens and 
the prototypic iNKT  cell agonist αGalCer fail to suppress 
cytotoxic T  lymphocytes (CTLs) and do not induce generation 
of FOXP3+ T  regulatory cells (TREGs), thus leading to longer 
survival of mice in a murine metastatic tumor model. Activated 
iNKT cells are able to modify MDSCs, transforming them back 
to a more immunogenic APC phenotype (58). MDSCs do not 
only include macrophages but also neutrophils, which acquire 
immunosuppressive properties such as IL-10-secretion, result-
ing in damping of antigen-specific T cell responses (59). It was 
shown that the acute-phase protein serum amyloid A 1 fosters 
iNKT-mediated conversion of suppressive activity of neutrophils. 
This immunomodulatory crosstalk between iNKT  cells and 
neutrophils is highly dependent on CD1d:TCR interaction (60). 
All-trans-retinoic acid (ATRA) is known to promote MDSC dif-
ferentiation (61, 62). Exposure of αGalCer-loaded MDSCs with 
ATRA has shown to restore immunogenicity of this immune 
subset in an iNKT cell-dependent way (63). These findings extend 
the previously reported arsenal of iNKT  cells to execute their 
immunomodulatory functions.
Like MDSCs, tumor-associated monocytes/macrophages 
(TAMs) are part of the tumor microenvironment but unlike 
MDSCs, TAMs are Gr1− (64). Primary human neuroblastoma cells 
are CD1d−, however, the tumor neuroblastoma microenvironment 
is highly enriched for CD68+/CD1d+ TAMs, which aliment tumor 
growth mainly through secretion of IL-6. CD1d-dependent kill-
ing of growth-promoting TAMs via iNKT cells decelerated tumor 
growth in a NOD/SCID human neuroblastoma xenograft model 
(65). Tumor necrosis factor related apoptosis inducing ligand 
(TRAIL)-expressing autologous or allogeneic CD4+ iNKT  cells 
induce apoptosis in myeloid leukemia cells derived from AML 
patients. However, TCR:CD1d interaction was not required for 
this effector function (66). Further TCR-independent effector 
functions include NKG2D-dependent cytotoxic degranulation 
(11), differential cytokine expression pattern upon stimulation 
with IL-2, IL-12, IL-18 (67) and potentiating NK-cell mediated 
cytotoxicity in an IL-2-dependent manner (68).
iNKT CeLL ACTivATiON BY DCs
The CD1 family is comprised of five isoforms that can be parti-
tioned in two groups. Group 1 consists of CD1a, CD1b, CD1c, 
and CD1e and group 2 only includes CD1d. While all isoforms 
can be found in humans, only CD1d is expressed in mice (69).
Dendritic cells constitutively express CD1d and may activate 
iNKT cells by presenting antigenic glycolipids. CD1d is a highly 
conserved non-polymorphic MHC class I-like transmembrane 
molecule; its expression is regulated by cytokines as well as 
through engagement of innate receptors (70). Similar to the 
structurally related MHC class I molecules, CD1d represents a 
heterodimer comprised of the CD1d heavy chain non-covalently 
coupled to β2-microglobulin. Many hematopoietic and non-
hematopoietic cell types express CD1d on their surface either 
constitutively or upon activation (71–75). However, in mice, 
constitutively CD1d-expressing DCs appear to be the most potent 
APCs for exogenous glycolipids (76–78). The interaction between 
iNKT cells and DCs is not unidirectional but characterized by 
reciprocal feedback loops depending on the chemical structure 
of the CD1d ligand as well as the nature of the APC (Figure 1) 
(9, 76). DCs acquire and CD1d present exogenous lipid antigens 
for the direct recognition by iNKT cells but may also transduce 
innate signals toward to the induction of iNKT cell responses (39, 
40, 79). In many cases, the activation of iNKT cells results from a 
combination of TCR-mediated recognition of cognate lipid anti-
gen and TCR-independent signals. For example, pattern recogni-
tion receptor (PRR)-bearing DCs will CD1d-present endogenous 
glycolipids in response to stimulation with pathogen-associated 
molecular patterns (39, 79–81). Recent studies suggest that PRR 
activation may specifically modulate the lysosomal processing 
of glycolipids in APCs to increase the abundance of endogenous 
iNKT cell agonists (80, 81). In concert with signals provided by 
pro-inflammatory cytokines secreted by PRR-activated DCs, the 
weaker TCR recognition of endogenous antigens is sufficient for 
iNKT cell activation (39, 40). To which extent similar cytokine 
signals are required for iNKT activation by microbes expressing 
stimulatory lipid antigens remains debated (13, 82). iNKT cells 
constitutively express the IL-12 receptor and PRR-mediated 
secretion of IL-12 by DCs triggers Stat4 phosphorylation and 
consecutive IFNγ secretion in iNKT cells (13, 83). Furthermore, 
direct cellular contact between DCs and iNKT  cells in a 
CD40:CD40L-dependent manner provides a strong feed-forward 
signal, resulting in additional IL-12 production by DCs and con-
secutive further upregulation of the IL-12 receptor on iNKT cells. 
CD40/CD40L as well as CD28:CD80/CD86 interactions are 
required for subsequent iNKT  cell-mediated-IFNγ secretion 
whereas IL-4-secretion was described to be solely dependent on 
CD28:CD80/CD86 interaction (83, 84). Co-administration of 
FiGURe 1 | interactions between invariant natural killer T (iNKT) cells and other immune cells. iNKT cells crosstalk with adaptive and innate immune cells 
including dendritic cells (DCs), B cells, natural killer (NK) cells, myeloid-derived suppressor cells (MDSCs), and conventional T cells. This reciprocal interaction is 
mediated via T cell receptor (TCR)-CD1d-recognition, interaction of co-stimulatory molecules or cytokines. Additionally, iNKT cells may interact with non-
hematopoietic cells that expose signs of infection, transformation, or cell stress.
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iNKT cell agonist αGalCer and OVA in CD40−/− and CD40L−/− 
mice leads to abrogation of CD4+ and CD8+ T  cell responses, 
while DCs are not affected in their ability to present antigen on 
MHC class I or II and are capable of upregulating CD80/86 (77). 
Recent reports show that artificial APCs loaded with iNKT cell 
agonists can activate and expand human iNKT cells in vitro as 
potently as autologous immature DCs. Engineering artificial 
APCs with differential association to co-stimulatory factors 
will help to obtain valuable insights into the crosstalk between 
iNKT cells and DCs and will foster our understanding of how to 
harness their therapeutic potential (85–87).
CD1d TRAFFiCKiNG iN MOUSe 
PROFeSSiONAL APCs
Similar to MHC class I molecules, CD1d molecules are synthe-
sized, folded, and equipped with β2-microglobulin in the ER 
(Figure  2) (88). Analogous to the placeholder function of the 
pseudopeptide CLIP in MHC class II, CD1d most likely leaves 
the ER with an endogenous lipid in its antigen-binding groove in 
order to maintain stability. The biochemical nature of these lipids 
and the exact mechanisms underlying the respective transfer 
processes are not fully elucidated yet. However, the ER chaperone 
protein microsomal triglyceride transfer protein (MTP) has been 
suggested to load phospholipids onto nascent CD1d (89). CD1d, 
after having passed several protein quality control checkpoints, 
follows the secretory pathway and is being guided to the Golgi 
apparatus and subsequently reaches the cell surface (88, 90). From 
there, CD1d is being internalized in clathrin-coated pits via the 
interaction of the adaptor protein complex 2 (AP2) and adaptor 
protein 3 (AP3) through tyrosine-based sorting motifs present 
in the cytoplasmic tail of CD1d, and subsequently delivered to 
endosomal compartments (91–93). The autophagic machinery 
assists in the recruitment of AP2 to CD1d molecules. Loss of 
the essential autophagy protein ATG5 in DCs impaired clathrin-
dependent internalization of CD1d molecules via AP2 and, thus, 
increased surface expression of stimulatory CD1d:glycolipid 
complexes, which resulted in enhanced iNKT activation (94).
Having generated a knock-in mouse by homologous recombi-
nation in which all CD1d is expressed as CD1d-EYFP, Sillé and 
colleagues described that in order to activate iNKT cells, endo-
somal sorting of CD1d is dependent on both its tyrosine-based 
FiGURe 2 | CD1d trafficking and loading in mouse dendritic cells. CD1d molecules are synthesized in the ER where they associate with β2-microglobulin. 
Microsomal triglyceride transfer protein (MTP) facilitates loading of ER-derived endogenous lipids onto CD1d in order to stabilize the molecule for further transport. In 
an independent pathway, some CD1d molecules associate in the ER with invariant chain (Ii). The Ii/CD1d complexes, after traveling through the trans-Golgi network, 
are directly guided to the lysosome. The non-Ii-associated CD1d molecules also pass the trans-Golgi network on their way to the plasma membrane. From there, 
facilitated by AP2 and members of the autophagy machinery, CD1d is internalized by clathrin-mediated endocytosis and guided toward endosomal compartments, 
where saposins, GM2 ganglioside activator (GM2A), and Niemann–Pick type C1 and C2 proteins (NPC1, NPC2) help exchanging endogenous lipids with exogenous 
or other endogenous lipids. From there, loaded CD1d may either be transported to the lysosome in an adaptor protein 3 (AP3)-dependent manner, or directly 
transported to the plasma membrane in order to interact with iNKT cells.
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sorting motif and on the association with the invariant chain (Ii) 
in peripheral DCs (95).
CD1d itself is unable to extract and acquire lipids from mem-
branes and, therefore, is in need of lipid transfer proteins (LTPs) 
that, in analogy to the MHC class II/H2-DM interaction, facilitate 
loading of antigens within the endosomal/lysosomal compart-
ment. Low molecular-weight proteins called saposins (A, B, C, 
and D), GM2 ganglioside activator (GM2A), and the Niemann–
Pick type C1 and C2 proteins (NPC1 and NPC2, respectively) 
have so far been identified to mediate the loading of lipids on 
CD1d molecules (96–99). Additionally, in the cases of saposins 
and GM2A, it was reported that these molecules also aid in the 
unloading of lipids from the CD1d antigen-binding groove (93). 
Following sampling of antigens in the endo/lysosomal system, 
loaded CD1d molecules are being recycled to the cell surface, 
similar to MHC class II molecules, and present bound antigens 
for iNKT cell activation.
eNDOGeNOUS AND eXOGeNOUS iNKT 
CeLL ANTiGeNS
Different from MHC class I or II-restricted antigen presentation 
during which processing of proteins or larger peptides results in 
smaller antigenic peptides presented by polymorphic antigen-
presenting molecules, monomorphic CD1d presents mainly 
unprocessed lipids of varying size and biochemical structure 
(100). Lipid antigens that stimulate CD1d-restricted iNKT cells 
comprise endogenous (also called self-lipids) and exogenous 
(e.g., microbial-derived) non-peptidic molecules. Within 
the mammalian class, self-lipids predominantly consist of 
6Keller et al. DC–NKT Interactions
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glycosphingolipids (GSLs) and phosphoglycerolipids (69). 
Endogenous self-lipids have been described to be crucial for 
thymic selection of iNKT cells via CD4+CD8+ thymocytes (28, 98) 
but might also be involved in modulating antiviral and antineo-
plastic iNKT activity in the periphery (57, 79, 101). With regards 
to MHC molecules, methodological advances in proteomics 
allowed for progressive elucidation of the MHC-binding immu-
nopeptidome in recent decades (102). In stark contrast, little is 
known about the endogenous lipid repertoire bound on CD1d 
in vivo, which is largely due to the fact that current techniques to 
extract CD1d molecules from cell membranes irretrievably entail 
the dissociation of CD1d-associated ligands. Although genera-
tion of secreted human CD1d molecules (sCD1d) by truncating 
the transmembrane and cytoplasmic domains shed some light 
on which lipid antigens are associated with CD1d (103), this 
approach implicates obvious shortcomings. Since the intracel-
lular cytoplasmic tail of CD1d is required for trafficking of CD1d 
through endolysosomal compartments in which lipid exchange 
and transfer occurs (28, 104), the detected lipidom is unlikely 
to reflect the in vivo setting. Therefore, the development of more 
refined techniques is required for the unequivocal identification 
of in vivo-relevant endogenous CD1d ligands.
The lysosomal glycosphingolipid isoglobotrihexosylceramide 
(iGb3), a moderate activator of iNKT cells, has been proposed to 
function as a self-lipid (105). However, the biological relevance of 
this finding warrants further investigation (106, 107). Other can-
didate self-lipids to be involved in iNKT cell development are the 
peroxisomal-derived ether-bonded phospholipids 1-O-1′-(Z)- 
hexadecenyl-2-hydroxy-sn-glycero-3-phosphoethanolamine 
and 1-O-1′, 9′-(Z,Z)-octadecadienyl-2-hydroxy-sn-glycero-3-
phosphoethanolamine. Not only depicted the synthetic plasmalo-
gen C16-lysophosphatidylethanolamine (pLPE) similar iNKT cell 
stimulatory capacities as the prototypical agonist αGalCer 
but mice deficient in glyceronephosphate O-acyltransferase 
(GNPAT), the peroxisomal enzyme essential for synthesis of 
ether lipids, showed impaired iNKT cell development. However, 
GNPAT−/− mice still harbored around 50% of iNKT cells found in 
GNPAT-competent mice (108). Other endogenous lipid antigens 
might, therefore, be involved in thymic selection of iNKT cells as 
well and the understanding of the relative contribution and dis-
tinct functions of a given endogenous CD1d ligand to iNKT cell 
biology will need further clarification.
Most exogenous CD1d ligands identified to date are of bacte-
rial origin. iNKT cell-activating lipid antigens have been found 
in Borrelia burgdorferi [α-galactosyldiacylglycerols (αGalDAGs)] 
(109), Sphingomonas spp. (α-glucuronosylceramides and α–galac-
turonosylceramides) (40, 110, 111), Streptococcus pneumoniae, and 
group B Streptococcus [α-glucosyldiacylglycerols (αGlcDAGs)] 
(112), Mycobacterium tuberculosis (phosphatidylinnositol man-
nosides) (113), Helicobacter pylori (cholesteryl α-glucoside) 
(114), and Bacteroides fragilis (α-galactosylceramides) (115). 
But also the porifera Agelas mauritianus (α-galactosylceramides) 
(8, 116) and the ascomycete Aspergillus fumigatus (asperamide B) 
(117) have been reported to contain antigenic lipids that activate 
iNKT cells.
The α-linked monoglycosylceramide αGalCer, initially iso-
lated from Agelas mauritianus was the first glycolipid identified 
to activate iNKT  cells. Its synthetic derivative KRN7000 has 
become a commonly used experimental tool in iNKT  cell 
research and to this day remains to be the most potent iNKT cell 
agonist (8, 116). Until recently, it was believed that mammalian 
cells are incapable of generating α-anomeric GSLs such as 
αGalCer. Making use of high-sensitivity biological assays, lipid 
immunopurification, and multiple reaction monitoring-mass 
spectrometry, Kain et al. reported that trace amounts of α-linked 
GSLs (both, αGluCer and αGalCer) are produced in mammalian 
cells and most likely function as endogenous ligands during 
thymic selection of iNKT cells (81).
iNKT CeLL-MeDiATeD MATURATiON AND 
LiCeNSiNG OF DCs
As a feedback loop, αGalCer-activated iNKT  cells contribute 
to maturation of DCs in vivo resulting in increased cell surface 
expression of MHC class II, the co-stimulatory molecules CD40, 
CD80, CD86, and the endocytic receptor DEC-205. iNKT cell-
matured DCs elicit specific CD4+ and CD8+ T  cell responses 
against a co-administered peptide. The observed DC maturation is 
highly dependent on iNKT cells since administration of αGalCer 
fails to induce DC maturation in Jα18−/− mice lacking iNKT cells 
(118). Challenge with OVA-expressing tumors demonstrated 
significant tumor resistance in animals that had been previously 
immunized with OVA in combination with the iNKT cell agonist 
αGalCer (119). In mice, the unique subset of CD8α+ DCs is 
able to cross-present extracellular antigens via MHC class I to 
evoke CTL responses (120). Both mouse (121) and human (122) 
studies have shown that cross-presentation is CD4+ T helper (TH) 
cell dependent. The interaction between mouse CD4+ TH cells 
and DCs leads to release of CCL3 and CCL4 attracting CCR5-
expressing CTLs to the site of cross-presentation (123). However, 
the CCR4-CCL17-dependent licensing of DCs by iNKT cells for 
cross-presentation has been described as an alternative pathway. 
iNKT  cell-mediated upregulation of CCL17 in DCs required 
CD1d and spatial interaction between iNKT  cells and DCs 
(124). Interestingly, Arora et al. reported that despite numerous 
cell types expressing high levels of CD1d, the CD8α+ DCs are 
the most competent presenters of lipid antigens in  vivo (125). 
Whether and to which extent these mechanisms are translated to 
humans, remains to be addressed.
FUNCTiONAL OUTCOMeS OF iNKT CeLL 
ACTivATiON
Recognition of CD1d:glycolipid complexes via the iNKT cell TCR 
can result in either pro-inflammatory TH1-biased or TH2-biased 
cytokine production by iNKT  cells (2, 18). Mechanisms that 
mediate such potentially opposing functional outcomes need to 
be taken into account in designing iNKT cell-targeting therapies. 
Differential expression of co-stimulatory signals on distinct APC 
subsets (126, 127) and the chemical structure of iNKT cell agonists, 
which target iNKT cell ligands to distinct APC populations (128, 
129) contribute to the functional outcome of iNKT cell activation. 
In serum, soluble iNKT cell agonists associate with lipoprotein 
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particles or are transported bound to serum LTPs, which facilitate 
glycolipid uptake by APCs and loading onto CD1d molecules 
(130–132). Several receptors mediate the uptake of glycolipids for 
CD1d presentation, including the low-density lipoprotein recep-
tor and the scavenger receptors SRA, SRB1, and CD36 (130, 132). 
Importantly, the specificity of this serum transport and receptor-
mediated uptake is largely influenced by minor modifications of 
the chemical structure of iNKT  cell agonists (133), suggesting 
that specific “targeting-motifs” could be used to direct glycolipid 
antigens toward distinct uptake pathways in order to modulate 
the resulting iNKT cell effector response (132). Besides affecting 
glycolipid uptake, the chemical structure of iNKT cell agonists 
may also influence the nature of the presenting APC as well as 
the context in which the antigen is CD1d presented. In general, 
the CD1d presentation of glycolipid antigens requires their access 
to the lysosomal loading compartment, which provides multiple 
glycosidases for antigen processing and lysosomal LTPs to assist 
in the solubilization and loading of glycolipids into CD1d (96–98, 
134–136). There is evidence that lipid antigens eliciting a TH2-
type iNKT  cell cytokine response do not require intracellular 
loading onto CD1d but may directly bind surface CD1d instead. 
Such TH2-biased iNKT  cell agonists typically possess short or 
unsaturated acyl chains, which increase their solubility in the 
aqueous environment but also favor a rapid displacement from 
CD1d upon recycling to the lysosome (137–140). The surface 
CD1d loading might bypass inclusion of such CD1d/lipid antigen 
complexes into lipid microdomains (139). Similarly, differential 
immune responses have been described for MHC class II mol-
ecules when presenting peptides either dependent or independ-
ent of lipid rafts (141). In addition, the anatomical context can 
modulate iNKT  cell cytokine responses. In mice, the principle 
presenters of αGalCer and other TH1-biased antigens in vivo are 
CD8α+ DEC-205+ DCs (76), while the presentation of TH2-biased 
iNKT  cell agonists was found to be more promiscuous, likely 
due to their ability to directly load onto cell surface CD1d (128). 
Furthermore, Lee et al. (142) showed that differential routes of 
lipid antigen application may dramatically alter the iNKT  cell 
activation pattern due to a distinct anatomical distribution of 
iNKT cell subsets.
THeRAPeUTiC iMPLiCATiONS
Their ability to mature DCs and to transactivate both CTLs and 
NK cells for tumor cell eradication (143, 144) reflect the potential 
of iNKT cells in improving cancer immunotherapy (Figure 3). 
However, in contrast to encouraging studies performed in experi-
mental models (145), clinical trials using direct administration of 
soluble αGalCer in cancer patients failed to show promising results 
(146). Aside from high interindividual variability in iNKT  cell 
frequencies and inefficient targeting of particular subsets of lipid 
presenting cells, direct administration of antigenic glycolipids 
was shown to induce PD1:PDL1-dependent long-term anergy 
(147–149) or induction of regulatory IL-10-producing iNKT cells 
(36, 150), which negatively affect antitumor responses (150). As 
an alternative to αGalCer administration, DCs can be glycolipid-
pulsed ex vivo followed by re-infusion. This strategy has proven 
to induce prolonged activation of iNKT  cells rather than a 
regulatory/anergic phenotype, inhibits metastasis in an experi-
mental melanoma model, and can expand human iNKT  cells 
in vivo (78, 151, 152). Additionally, adoptive transfer of αGalCer-
pulsed matured DCs expands iNKT  cells in advanced stage 
cancer patients (153). A clinical phase I study in a limited number 
of individuals with metastatic malignancies reported that transfer 
of immature monocyte-derived DCs loaded with αGalCer was 
associated with a stronger recall response (154). Matured DCs 
as compared to immature DCs increased the observed beneficial 
effects significantly (153, 154). Another phase I trial during which 
patients with head and neck squamous cell carcinoma (HNSCC) 
were treated via singular co-administration of autologous in vitro 
expanded iNKT cells (intraarterial) and submucosal application 
of αGalCer-loaded APCs showed partial clinical response (155). 
In a small phase II clinical study in HNSCC patients using the 
same treatment regimen, 50% of the patients depicted tumor 
regression while 50% showed stable disease (156). Promising 
results were reported from a phase I-II study in non-small cell 
lung cancer patients: sequential intravenous administration 
of αGalCer-pulsed PBMCs increased the frequencies of IFNγ-
producing cells in a majority of patients. This iNKT cell-mediated 
TH1 skewing in responders was associated with significantly 
prolonged median survival time (157). In a follow-up study, two 
candidate genes, LTB4DH and DPYSL3, were proposed to predict 
responsiveness to abovementioned treatment regimen (158). Late 
stage cancer patients often times are immune suppressed and 
retrieving enough APCs from these individuals for autologous 
transfer might prove difficult. Therefore, novel artificial APC 
constructs may help to circumvent lack of appropriate autologous 
APC numbers (85–87). Moreover, novel glycolipid-antigen deliv-
ery systems that systematically target relevant APC populations 
are currently being investigated. Some of these nanovector sys-
tems already show promising results. αGalCer-containing silica 
microspheres, poly(lactic-co-glycolic acid) (PLGA) polymers, 
and modified liposomes have already been reported to efficiently 
elicit iNKT cell responses (159–161). In order to initiate in situ 
responses of DCs, artificial adjuvant vector cell systems have 
been recently introduced. Herein, allogeneic CD1d-expressing 
NIH3T3 fibroblasts loaded with αGalCer were transfected with 
target-antigen mRNA. Injection of NIH3T3 fibroblasts lead to 
activation of iNKT  cells, consecutive maturation of DCs, and 
activation of NK cells and antigen-specific CTLs. Animals that 
were immunized with adjuvant vector cells show potent immu-
nity against antigen-bearing tumors. Interestingly, memory CTL 
responses can still be detected 12  months after initial single 
injection (143, 162).
Humans, as compared to mice, show high interindividual 
variability in iNKT cell frequencies. Patients with low steady-state 
numbers of iNKT cells might not efficiently profit from autolo-
gous transfer of lipid-pulsed APCs. Mouse embryonic fibroblast-
derived induced pluripotent stem cells (iPSCs) can readily 
differentiate into functional iNKT  cells. These iPSC-derived 
iNKT cells are able to produce IFNγ and mediate anti-neoplastic 
effects in  vivo (163). Therefore, patients with low iNKT  cell 
frequencies may be reconstituted with iPSC-derived iNKT cells 
as an efficient means to fully harness their immunomodulatory 
potential (143).
FiGURe 3 | Potential and already implemented invariant natural killer T cells (iNKT) cellular therapeutic approaches. Illustrates different application 
modes of iNKT-based therapies. (A) Direct administration of iNKT cell agonist αGalCer. This has so far not proven to be efficacious due to long-term anergy and 
regulatory phenotype of iNKT cells following αGalCer administration. (B) Isolation, purification, in vitro expansion, and re-infusion of peripheral iNKT cells,  
(C) isolation of PBMCs and subsequent generation of monocyte-derived DCs which, after lipid-pulsing, are re-infused (either alone or in combination with in vitro 
expanded autologous iNKT cells), (D) novel and future approaches include chimeric antigen receptor (CAR)-iNKT cell generation, artificial adjuvant vector cell 
systems, αGalCer-containing silica microspheres, PLGA polymers, and modified liposomes.
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First attempts in using engineered iNKT cells with chimeric 
antigen receptors (CARs) show promising results. CAR-bearing 
iNKT  cells home to designated tumor sites, eradicate tumor 
cells, and effectively execute cytotoxicity against TAMs without 
inducing graft-versus-host disease (164). Additionally, CD62L+ 
CD19-specific CAR-bearing iNKT  cells show potent immuno-
therapeutic efficacy in a B cell lymphoma model (165).
In conclusion, murine and clinical trials performed to date 
demonstrate that therapeutic strategies that harness the biology 
of iNKT cells are generally well tolerated and, in some cases, effec-
tive in inducing tumor regression and prolonged survival. All of 
the tested and currently investigated strategies harness both the 
powerful cytolytic and adjuvant activity of iNKT cells in order to 
enhance protective antitumor immune responses. In order to fully 
exploit their therapeutic potential, it will not only be essential to 
elucidate the differential effector functions and modes of activa-
tion of individual iNKT cell subsets but also the immunological 
contexts and transcriptional programs that direct CD24hi/CD69+ 
iNKT cell progenitors into development toward specific iNKT cell 
subpopulations as well as determinants that gear specific iNKT cell 
subsets to distinct anatomical sites (31, 142, 166). Profound 
mechanistic insight into understanding how DCs activate and 
instruct iNKT cells and which factors regulate iNKT cell responses 
are prerequisites for improving the efficacy of iNKT cell-targeting 
therapies. In addition, clinical trials will be instrumental in identi-
fying the optimal ligands and APC populations to induce vigorous 
iNKT cell activation and in determining the routes and intervals of 
administration to achieve sustained antitumor immunity.
AUTHOR CONTRiBUTiONS
CWK, SF, and JDL participated in drafting the article and revising 
it critically for important intellectual content. All authors gave 
final approval of the submitted manuscript.
9Keller et al. DC–NKT Interactions
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 570
ReFeReNCeS
1. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The bur-
geoning family of unconventional T cells. Nat Immunol (2015) 16:1114–23. 
doi:10.1038/ni.3298 
2. Salio M, Silk JD, Jones EY, Cerundolo V. Biology of CD1- and MR1-
restricted T  cells. Annu Rev Immunol (2014) 32:323–66. doi:10.1146/
annurev-immunol-032713-120243 
3. Macho-Fernandez E, Brigl M. The extended family of CD1d-restricted 
NKT  cells: sifting through a mixed bag of TCRs, antigens, and functions. 
Front Immunol (2015) 6:362. doi:10.3389/fimmu.2015.00362 
4. Marrero I, Ware R, Kumar V. Type II NKT  cells in inflammation, auto-
immunity, microbial immunity, and cancer. Front Immunol (2015) 6:316. 
doi:10.3389/fimmu.2015.00316 
5. Budd RC, Miescher GC, Howe RC, Lees RK, Bron C, MacDonald HR. 
Developmentally regulated expression of T  cell receptor beta chain 
variable domains in immature thymocytes. J Exp Med (1987) 166:577–82. 
doi:10.1084/jem.166.2.577 
6. Fowlkes BJ, Kruisbeek AM, Ton-That H, Weston MA, Coligan JE, Schwartz RH, 
et al. A novel population of T-cell receptor alpha beta-bearing thymocytes 
which predominantly expresses a single V beta gene family. Nature (1987) 
329:251–4. doi:10.1038/329251a0 
7. Imai K, Kanno M, Kimoto H, Shigemoto K, Yamamoto S, Taniguchi M. 
Sequence and expression of transcripts of the T-cell antigen receptor 
alpha-chain gene in a functional, antigen-specific suppressor-T-cell hybrid-
oma. Proc Natl Acad Sci U S A (1986) 83:8708–12. doi:10.1073/pnas.83. 
22.8708 
8. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et  al. 
CD1d-restricted and TCR-mediated activation of valpha14 NKT  cells 
by glycosylceramides. Science (1997) 278:1626–9. doi:10.1126/science. 
278.5343.1626 
9. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate 
activation scheme linked to diverse effector functions. Nat Rev Immunol 
(2013) 13:101–17. doi:10.1038/nri3369 
10. Taniguchi M, Harada M, Dashtsoodol N, Kojo S. Discovery of NKT  cells 
and development of NKT cell-targeted anti-tumor immunotherapy. Proc Jpn 
Acad Ser B Phys Biol Sci (2015) 91:292–304. doi:10.2183/pjab.91.292 
11. Kuylenstierna C, Björkström NK, Andersson SK, Sahlström P, Bosnjak L, 
Paquin-Proulx D, et  al. NKG2D performs two functions in invariant 
NKT  cells: direct TCR-independent activation of NK-like cytolysis and 
co-stimulation of activation by CD1d. Eur J Immunol (2011) 41:1913–23. 
doi:10.1002/eji.200940278 
12. Shimizu K, Sato Y, Shinga J, Watanabe T, Endo T, Asakura M, et al. KLRG+ 
invariant natural killer T cells are long-lived effectors. Proc Natl Acad Sci U S 
A (2014) 111:12474–9. doi:10.1073/pnas.1406240111 
13. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, Barton N, et al. 
Innate and cytokine-driven signals, rather than microbial antigens, dominate 
in natural killer T cell activation during microbial infection. J Exp Med (2011) 
208:1163–77. doi:10.1084/jem.20102555 
14. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification 
of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp 
Med (2000) 191:1895–903. doi:10.1084/jem.191.11.1895 
15. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, 
et al. Tracking the response of natural killer T cells to a glycolipid antigen 
using CD1d tetramers. J Exp Med (2000) 192:741–54. doi:10.1084/
jem.192.5.741 
16. Godfrey DI, Macdonald HR, Kronenberg M, Smyth MJ, Van Kaer L. 
NKT cells: what’s in a name? Nat Rev Immunol (2004) 4:231–7. doi:10.1038/
nri1309 
17. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. 
CD1 recognition by mouse NK1+ T lymphocytes. Science (1995) 268:863–5. 
doi:10.1126/science.7538697 
18. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 
(2007) 25:297–336. doi:10.1146/annurev.immunol.25.022106.141711 
19. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. Cutting 
edge: cross-talk between cells of the innate immune system: NKT cells rapidly 
activate NK cells. J Immunol (1999) 163:4647–50. 
20. Chang P-P, Barral P, Fitch J, Pratama A, Ma CS, Kallies A, et al. Identification 
of Bcl-6-dependent follicular helper NKT cells that provide cognate help for 
B cell responses. Nat Immunol (2012) 13:35–43. doi:10.1038/ni.2166 
21. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al. 
CD1d-mediated recognition of an alpha-galactosylceramide by natural killer 
T cells is highly conserved through mammalian evolution. J Exp Med (1998) 
188:1521–8. doi:10.1084/jem.188.8.1521 
22. Hammond KJ, Kronenberg M. Natural killer T cells: natural or unnatural reg-
ulators of autoimmunity? Curr Opin Immunol (2003) 15:683–9. doi:10.1016/j.
coi.2003.09.014 
23. Schipper HS, Rakhshandehroo M, van de Graaf SF, Venken K, Koppen A, 
Stienstra R, et  al. Natural killer T  cells in adipose tissue prevent insulin 
resistance. J Clin Invest (2012) 122:3343–54. doi:10.1172/JCI62739 
24. Watarai H, Nakagawa R, Omori-Miyake M, Dashtsoodol N, Taniguchi M. 
Methods for detection, isolation and culture of mouse and human invariant 
NKT cells. Nat Protoc (2008) 3:70–8. doi:10.1038/nprot.2007.515 
25. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T  cell 
defects and human disease. Nat Rev Immunol (2011) 11:131–42. doi:10.1038/ 
nri2904 
26. Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, 
et  al. T  cell receptor signal strength in Treg and iNKT  cell development 
demonstrated by a novel fluorescent reporter mouse. J Exp Med (2011) 
208:1279–89. doi:10.1084/jem.20110308 
27. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state pro-
duction of IL-4 modulates immunity in mouse strains and is determined by 
lineage diversity of iNKT cells. Nat Immunol (2013) 14:1146–54. doi:10.1038/
ni.2731 
28. Chiu YH, Park SH, Benlagha K, Forestier C, Jayawardena-Wolf J, Savage PB, 
et al. Multiple defects in antigen presentation and T cell development by mice 
expressing cytoplasmic tail-truncated CD1d. Nat Immunol (2002) 3:55–60. 
doi:10.1038/ni740 
29. Sandberg JK, Stoddart CA, Brilot F, Jordan KA, Nixon DF. Development of 
innate CD4+ alpha-chain variable gene segment 24 (Valpha24) natural killer 
T cells in the early human fetal thymus is regulated by IL-7. Proc Natl Acad 
Sci U S A (2004) 101:7058–63. doi:10.1073/pnas.0305986101 
30. Seiler MP, Mathew R, Liszewski MK, Spooner CJ, Barr K, Meng F, et  al. 
Elevated and sustained expression of the transcription factors Egr1 and 
Egr2 controls NKT lineage differentiation in response to TCR signaling. Nat 
Immunol (2012) 13:264–71. doi:10.1038/ni.2230 
31. Gapin L. Development of invariant natural killer T cells. Curr Opin Immunol 
(2016) 39:68–74. doi:10.1016/j.coi.2016.01.001 
32. Kim EY, Lynch L, Brennan PJ, Cohen NR, Brenner MB. The transcriptional 
programs of iNKT  cells. Semin Immunol (2015) 27:26–32. doi:10.1016/j.
smim.2015.02.005 
33. Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, et al. The 
transcription factor PLZF directs the effector program of the NKT  cell 
lineage. Immunity (2008) 29:391–403. doi:10.1016/j.immuni.2008.07.011 
34. Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, et al. The 
BTB-zinc finger transcriptional regulator PLZF controls the development 
of invariant natural killer T  cell effector functions. Nat Immunol (2008) 
9:1055–64. doi:10.1038/ni.1641 
FUNDiNG
CWK was supported by a scholarship provided by the German 
Research Foundation (DFG grant KE 1831/1-1) and a scholarship 
by the University of Zurich (Forschungskredit FK-14-021). SF is 
supported by grants from the Swiss National Science Foundation 
(152872 and 157702), the Vontobel-Stiftung, the University of 
Bern Research Foundation, and the 3R Research Foundation. JDL 
is supported by the Swiss National Science Foundation (31003A-
169664), the Novartis Foundation for medical-biological research, 
the Sassella Foundation, the Hartmann Müller Foundation, and 
the Swiss Multiple Sclerosis Society.
10
Keller et al. DC–NKT Interactions
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 570
35. Engel I, Seumois G, Chavez L, Samaniego-Castruita D, White B, Chawla A, 
et al. Innate-like functions of natural killer T cell subsets result from highly 
divergent gene programs. Nat Immunol (2016) 17:728–39. doi:10.1038/
ni.3437 
36. Lynch L, Michelet X, Zhang S, Brennan PJ, Moseman A, Lester C, et  al. 
Regulatory iNKT cells lack expression of the transcription factor PLZF and 
control the homeostasis of T(reg) cells and macrophages in adipose tissue. 
Nat Immunol (2015) 16:85–95. doi:10.1038/ni.3047 
37. Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, et  al. 
Adipose tissue invariant NKT  cells protect against diet-induced obesity 
and metabolic disorder through regulatory cytokine production. Immunity 
(2012) 37:574–87. doi:10.1016/j.immuni.2012.06.016 
38. Kanda M, Yamanaka H, Kojo S, Usui Y, Honda H, Sotomaru Y, et  al. 
Transcriptional regulator Bhlhe40 works as a cofactor of T-bet in the reg-
ulation of IFN-γ production in iNKT cells. Proc Natl Acad Sci U S A (2016) 
113(24):E3394–402. doi:10.1073/pnas.1604178113 
39. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-
restricted natural killer T  cell activation during microbial infection. Nat 
Immunol (2003) 4:1230–7. doi:10.1038/ni1002 
40. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C, Zhou D, et al. Exogenous 
and endogenous glycolipid antigens activate NKT  cells during microbial 
infections. Nature (2005) 434:525–9. doi:10.1038/nature03408 
41. Wilson MT, Johansson C, Olivares-Villagómez D, Singh AK, Stanic AK, 
Wang C-R, et al. The response of natural killer T cells to glycolipid antigens 
is characterized by surface receptor down-modulation and expansion. Proc 
Natl Acad Sci U S A (2003) 100:10913–8. doi:10.1073/pnas.1833166100 
42. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. 
Sequential activation of NKT  cells and NK  cells provides effective innate 
immunotherapy of cancer. J Exp Med (2005) 201:1973–85. doi:10.1084/
jem.20042280 
43. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, 
et al. Sequential production of interferon-gamma by NK1.1(+) T cells and 
natural killer cells is essential for the antimetastatic effect of alpha-galactosyl-
ceramide. Blood (2002) 99:1259–66. doi:10.1182/blood.V99.4.1259 
44. Schneiders FL, de Bruin RC, Santegoets SJ, Bonneville M, Scotet E, Scheper RJ, 
et  al. Activated iNKT  cells promote Vγ9Vδ2-T  cell anti-tumor effector 
functions through the production of TNF-α. Clin Immunol (2012) 142: 
194–200. doi:10.1016/j.clim.2011.10.006 
45. Paget C, Bialecki E, Fontaine J, Vendeville C, Mallevaey T, Faveeuw C, et al. 
Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxy-
nucleotides. J Immunol (2009) 182:1846–53. doi:10.4049/jimmunol.0802492 
46. Leadbetter EA, Brigl M, Illarionov P, Cohen N, Luteran MC, Pillai S, et al. NK 
T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad 
Sci U S A (2008) 105:8339–44. doi:10.1073/pnas.0801375105 
47. King IL, Fortier A, Tighe M, Dibble J, Watts GFM, Veerapen N, et  al. 
Invariant natural killer T cells direct B cell responses to cognate lipid antigen 
in an IL-21-dependent manner. Nat Immunol (2012) 13:44–50. doi:10.1038/
ni.2172 
48. Bialecki E, Paget C, Fontaine J, Capron M, Trottein F, Faveeuw C. Role of 
marginal zone B lymphocytes in invariant NKT cell activation. J Immunol 
(2009) 182:6105–13. doi:10.4049/jimmunol.0802273 
49. Zietara N, Łyszkiewicz M, Krueger A, Weiss S. ICOS-dependent stimulation 
of NKT cells by marginal zone B cells. Eur J Immunol (2011) 41:3125–34. 
doi:10.1002/eji.201041092 
50. Vomhof-Dekrey EE, Yates J, Hägglöf T, Lanthier P, Amiel E, Veerapen N, 
et  al. Cognate interaction with iNKT  cells expands IL-10-producing B 
regulatory cells. Proc Natl Acad Sci U S A (2015) 112:12474–9. doi:10.1073/
pnas.1504790112 
51. Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJ, Hayakawa Y, Sidobre S, 
et  al. Glycolipid antigen drives rapid expansion and sustained cytokine 
production by NK T  cells. J Immunol (2003) 171:4020–7. doi:10.4049/
jimmunol.171.8.4020 
52. Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L, et  al. 
Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised 
for rapid effector function. J Exp Med (2003) 198:1069–76. doi:10.1084/
jem.20030630 
53. Matsuda JL, Gapin L, Baron JL, Sidobre S, Stetson DB, Mohrs M, et al. Mouse 
V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. 
Proc Natl Acad Sci U S A (2003) 100:8395–400. doi:10.1073/pnas.1332805100 
54. Nagaleekar VK, Sabio G, Aktan I, Chant A, Howe IW, Thornton TM, et al. 
Translational control of NKT  cell cytokine production by p38 MAPK. 
J Immunol (2011) 186:4140–6. doi:10.4049/jimmunol.1002614 
55. Wingender G, Krebs P, Beutler B, Kronenberg M. Antigen-specific cytotox-
icity by invariant NKT cells in vivo is CD95/CD178-dependent and is cor-
related with antigenic potency. J Immunol (2010) 185:2721–9. doi:10.4049/
jimmunol.1001018 
56. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived 
suppressor cells in the tumor microenvironment. Trends Immunol (2016) 
37:208–20. doi:10.1016/j.it.2016.01.004 
57. De Santo C, Salio M, Masri SH, Lee LY, Dong T, Speak AO, et al. Invariant 
NKT cells reduce the immunosuppressive activity of influenza A virus-in-
duced myeloid-derived suppressor cells in mice and humans. J Clin Invest 
(2008) 118:4036–48. doi:10.1172/JCI36264 
58. Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA, Kang CY. Immunosuppressive 
myeloid-derived suppressor cells can be converted into immunogenic APCs 
with the help of activated NKT  cells: an alternative cell-based antitumor 
vaccine. J Immunol (2009) 182:1818–28. doi:10.4049/jimmunol.0802430 
59. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-
Rosenberg S, et  al. The terminology issue for myeloid-derived suppressor 
cells. Cancer Res (2007) 67:425; author reply 426. doi:10.1158/0008-5472.
CAN-06-3037 
60. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, et al. Invariant 
NKT cells modulate the suppressive activity of IL-10-secreting neutrophils 
differentiated with serum amyloid A. Nat Immunol (2010) 11:1039–46. 
doi:10.1038/ni.1942 
61. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kübler H, et al. Reversal 
of myeloid cell-mediated immunosuppression in patients with metastatic 
renal cell carcinoma. Clin Cancer Res (2008) 14:8270–8. doi:10.1158/1078-
0432.CCR-08-0165 
62. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-
trans-retinoic acid eliminates immature myeloid cells from tumor-bearing 
mice and improves the effect of vaccination. Cancer Res (2003) 63:4441–9. 
63. Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY. The restoration of 
myeloid-derived suppressor cells as functional antigen-presenting cells by 
NKT  cell help and all-trans-retinoic acid treatment. Int J Cancer (2012) 
131:741–51. doi:10.1002/ijc.26411 
64. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of 
the immune system. Nat Rev Immunol (2009) 9:162–74. doi:10.1038/nri2506 
65. Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, Sposto R, et al. Valpha24-
invariant NKT cells mediate antitumor activity via killing of tumor-associated 
macrophages. J Clin Invest (2009) 119:1524–36. doi:10.1172/JCI37869 
66. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, et al. TRAIL 
expression by activated human CD4(+)V alpha 24NKT cells induces in vitro 
and in vivo apoptosis of human acute myeloid leukemia cells. Blood (2001) 
97:2067–74. doi:10.1182/blood.V97.7.2067 
67. Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Cytokine production 
and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the com-
bination of IL-12 and IL-18. J Immunol (2000) 165:1847–53. doi:10.4049/
jimmunol.165.4.1847 
68. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, et  al. 
Human NKT  cells mediate antitumor cytotoxicity directly by recognizing 
target cell CD1d with bound ligand or indirectly by producing IL-2 to acti-
vate NK  cells. J Immunol (2001) 167:3114–22. doi:10.4049/jimmunol.167. 
6.3114 
69. Mori L, Lepore M, De Libero G. The immunology of CD1- and MR1-
restricted T  cells. Annu Rev Immunol (2016) 34:479–510. doi:10.1146/
annurev-immunol-032414-112008 
70. Sköld M, Xiong X, Illarionov PA, Besra GS, Behar SM. Interplay of cytokines 
and microbial signals in regulation of CD1d expression and NKT cell activa-
tion. J Immunol (2005) 175:3584–93. doi:10.4049/jimmunol.175.6.3584 
71. Busshoff U, Hein A, Iglesias A, Dörries R, Régnier-Vigouroux A. CD1 
expression is differentially regulated by microglia, macrophages and T cells 
in the central nervous system upon inflammation and demyelination. 
J Neuroimmunol (2001) 113:220–30. doi:10.1016/S0165-5728(00)00450-1 
72. de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, et  al. 
Production of profibrotic cytokines by invariant NKT cells characterizes cir-
rhosis progression in chronic viral hepatitis. J Immunol (2004) 173:1417–25. 
doi:10.4049/jimmunol.173.2.1417 
11
Keller et al. DC–NKT Interactions
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 570
73. Canchis PW, Bhan AK, Landau SB, Yang L, Balk SP, Blumberg RS. Tissue 
distribution of the non-polymorphic major histocompatibility complex class 
I-like molecule, CD1d. Immunology (1993) 80:561–5. 
74. Balk SP, Burke S, Polischuk JE, Frantz ME, Yang L, Porcelli S, et  al. Beta 
2-microglobulin-independent MHC class Ib molecule expressed by 
human intestinal epithelium. Science (1994) 265:259–62. doi:10.1126/
science.7517575 
75. Blumberg RS, Terhorst C, Bleicher P, McDermott FV, Allan CH, Landau SB, 
et al. Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by 
human intestinal epithelial cells. J Immunol (1991) 147:2518–24. 
76. Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Goldberg MF, et  al. A 
single subset of dendritic cells controls the cytokine bias of natural killer 
T cell responses to diverse glycolipid antigens. Immunity (2014) 40:105–16. 
doi:10.1016/j.immuni.2013.12.004 
77. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to 
adaptive immunity via maturing dendritic cells in vivo requires CD40 liga-
tion in addition to antigen presentation and CD80/86 costimulation. J Exp 
Med (2004) 199:1607–18. doi:10.1084/jem.20040317 
78. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-
producing NKT response induced with alpha-galactosylceramide-loaded 
DCs. Nat Immunol (2002) 3:867–74. doi:10.1038/ni827 
79. Paget C, Mallevaey T, Speak AO, Torres D, Fontaine J, Sheehan KC, et  al. 
Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic 
cells requires type I interferon and charged glycosphingolipids. Immunity 
(2007) 27:597–609. doi:10.1016/j.immuni.2007.08.017 
80. Darmoise A, Teneberg S, Bouzonville L, Brady RO, Beck M, Kaufmann SH, 
et  al. Lysosomal alpha-galactosidase controls the generation of self lipid 
antigens for natural killer T cells. Immunity (2010) 33:216–28. doi:10.1016/j.
immuni.2010.08.003 
81. Kain L, Webb B, Anderson BL, Deng S, Holt M, Constanzo A, et  al. The 
identification of the endogenous ligands of natural killer T cells reveals the 
presence of mammalian &alpha;-linked glycosylceramides. Immunity (2014) 
41:543–54. doi:10.1016/j.immuni.2014.08.017 
82. Holzapfel KL, Tyznik AJ, Kronenberg M, Hogquist KA. Antigen-dependent 
versus -independent activation of invariant NKT  cells during infection. 
J Immunol (2014) 192:5490–8. doi:10.4049/jimmunol.1400722 
83. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, et al. The 
natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its 
immunopotentiating effect by inducing interleukin (IL)-12 production by 
dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med (1999) 
189:1121–8. doi:10.1084/jem.189.7.1121 
84. Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. 
Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and 
CD40 costimulatory pathways. J Immunol (2001) 166:6012–8. doi:10.4049/
jimmunol.166.10.6012 
85. Sun W, Subrahmanyam PB, East JE, Webb TJ. Connecting the dots: artifi-
cial antigen presenting cell-mediated modulation of natural killer T  cells. 
J Interferon Cytokine Res (2012) 32:505–16. doi:10.1089/jir.2012.0045 
86. Shiratsuchi T, Schneck J, Kawamura A, Tsuji M. Human CD1 dimeric 
proteins as indispensable tools for research on CD1-binding lipids and CD1- 
restricted T  cells. J Immunol Methods (2009) 345:49–59. doi:10.1016/ 
j.jim.2009.04.002 
87. East JE, Sun W, Webb TJ. Artificial antigen presenting cell (aAPC) mediated 
activation and expansion of natural killer T cells. J Vis Exp (2012) (70):e4333. 
doi:10.3791/4333 
88. Kim HS, Garcia J, Exley M, Johnson KW, Balk SP, Blumberg RS. Biochemical 
characterization of CD1d expression in the absence of beta2-microglobulin. 
J Biol Chem (1999) 274:9289–95. doi:10.1074/jbc.274.14.9289 
89. Dougan SK, Salas A, Rava P, Agyemang A, Kaser A, Morrison J, et  al. 
Microsomal triglyceride transfer protein lipidation and control of CD1d 
on antigen-presenting cells. J Exp Med (2005) 202:529–39. doi:10.1084/
jem.20050183 
90. Kang SJ, Cresswell P. Calnexin, calreticulin, and ERp57 cooperate in 
disulfide bond formation in human CD1d heavy chain. J Biol Chem (2002) 
277:44838–44. doi:10.1074/jbc.M207831200 
91. Elewaut D, Lawton AP, Nagarajan NA, Maverakis E, Khurana A, Honing S, 
et al. The adaptor protein AP-3 is required for CD1d-mediated antigen pre-
sentation of glycosphingolipids and development of V 14i NKT cells. J Exp 
Med (2003) 198:1133–46. doi:10.1084/jem.20030143 
92. Cernadas M, Sugita M, van der Wel N, Cao X, Gumperz JE, Maltsev S, et al. 
Lysosomal localization of murine CD1d mediated by AP-3 is necessary 
for NK T  cell development. J Immunol (2003) 171:4149–55. doi:10.4049/
jimmunol.171.8.4149 
93. Vartabedian VF, Savage PB, Teyton L. The processing and presentation of lip-
ids and glycolipids to the immune system. Immunol Rev (2016) 272:109–19. 
doi:10.1111/imr.12431 
94. Keller CW, Loi M, Ewert S, Quast I, Theiler R, Gannagé M, et  al. The 
autophagy machinery restrains iNKT  cell activation through CD1D1 
internalization. Autophagy (2017) 15:1–12. doi:10.1080/15548627.2017.1
297907 
95. Sille FCM, Boxem M, Sprengers D, Veerapen N, Besra G, Boes M. Distinct 
requirements for CD1d intracellular transport for development of V 14 
iNKT cells. J Immunol (2009) 183:1780–8. doi:10.4049/jimmunol.0901354 
96. Zhou D, Cantu C, Sagiv Y, Schrantz N, Kulkarni AB, Qi X, et  al. Editing 
of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 
(2004) 303:523–7. doi:10.1126/science.1092009 
97. Kang SJ, Cresswell P. Saposins facilitate CD1d-restricted presentation 
of an exogenous lipid antigen to T  cells. Nat Immunol (2004) 5:175–81. 
doi:10.1038/ni1034 
98. Schrantz N, Sagiv Y, Liu Y, Savage PB, Bendelac A, Teyton L. The Niemann-
Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules 
and contributes to the thymic selection of NKT  cells. J Exp Med (2007) 
204:841–52. doi:10.1084/jem.20061562 
99. Sagiv Y, Hudspeth K, Mattner J, Schrantz N, Stern RK, Zhou D, et al. Cutting 
edge: impaired glycosphingolipid trafficking and NKT cell development in 
mice lacking Niemann-Pick type C1 protein. J Immunol (2006) 177:26–30. 
doi:10.4049/jimmunol.177.1.26 
100. Ly D, Moody DB. The CD1 size problem: lipid antigens, ligands, and scaf-
folds. Cell Mol Life Sci (2014) 71:3069–79. doi:10.1007/s00018-014-1603-6 
101. Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, et al. Hepatitis B 
virus-induced lipid alterations contribute to natural killer T cell-dependent 
protective immunity. Nat Med (2012) 18:1060–8. doi:10.1038/nm.2811 
102. Stern LJ, Santambrogio L. The melting pot of the MHC II peptidome. Curr 
Opin Immunol (2016) 40:70–7. doi:10.1016/j.coi.2016.03.004 
103. Cox D, Fox L, Tian R, Bardet W, Skaley M, Mojsilovic D, et al. Determination 
of cellular lipids bound to human CD1d molecules. PLoS One (2009) 4:e5325. 
doi:10.1371/journal.pone.0005325 
104. Chiu YH, Jayawardena J, Weiss A, Lee D, Park SH, Dautry-Varsat A, et al. 
Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in 
different cellular compartments. J Exp Med (1999) 189:103–10. doi:10.1084/
jem.189.1.103 
105. Zhou D, Mattner J, Cantu C, Schrantz N, Yin N, Gao Y, et  al. Lysosomal 
glycosphingolipid recognition by NKT  cells. Science (2004) 306:1786–9. 
doi:10.1126/science.1103440 
106. Speak AO, Salio M, Neville DC, Fontaine J, Priestman DA, Platt N, et  al. 
Implications for invariant natural killer T cell ligands due to the restricted 
presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci U S 
A (2007) 104:5971–6. doi:10.1073/pnas.0607285104 
107. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Gröne H-J. Normal 
development and function of invariant natural killer T  cells in mice with 
isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci U S A 
(2007) 104:5977–82. doi:10.1073/pnas.0611139104 
108. Facciotti F, Ramanjaneyulu GS, Lepore M, Sansano S, Cavallari M, 
Kistowska M, et al. Peroxisome-derived lipids are self antigens that stimulate 
invariant natural killer T cells in the thymus. Nat Immunol (2012) 13:474–80. 
doi:10.1038/ni.2245 
109. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia MR, et  al. 
Natural killer T  cells recognize diacylglycerol antigens from pathogenic 
bacteria. Nat Immunol (2006) 7:978–86. doi:10.1038/ni1380 
110. Kinjo Y, Wu D, Kim G, Xing G-W, Poles MA, Ho DD, et  al. Recognition 
of bacterial glycosphingolipids by natural killer T  cells. Nature (2005) 
434:520–5. doi:10.1038/nature03407 
111. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingo-
lipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. 
Eur J Immunol (2005) 35:1692–701. doi:10.1002/eji.200526157 
112. Kinjo Y, Illarionov P, Véla JL, Pei B, Girardi E, Li X, et al. Invariant natural 
killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. 
Nat Immunol (2011) 12:966–74. doi:10.1038/ni.2096 
12
Keller et al. DC–NKT Interactions
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 570
113. Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, et al. 
Mycobacterial phosphatidylinositol mannoside is a natural antigen for 
CD1d-restricted T  cells. Proc Natl Acad Sci U S A (2004) 101:10685–90. 
doi:10.1073/pnas.0403787101 
114. Ito Y, Véla JL, Matsumura F, Hoshino H, Tyznik A, Lee H, et al. Helicobacter 
pylori cholesteryl α-glucosides contribute to its pathogenicity and immune 
response by natural killer T cells. PLoS One (2013) 8:e78191. doi:10.1371/
journal.pone.0078191 
115. Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, 
Kronenberg M, et  al. Production of α-galactosylceramide by a prominent 
member of the human gut microbiota. PLoS Biol (2013) 11:e1001610. 
doi:10.1371/journal.pbio.1001610 
116. Natori T, Koezuka Y, Higa T. Agelasphins, novel α-galactosylceramides from 
the marine sponge Agelas mauritianus. Tetrahedron Lett (1993) 34:5591–2. 
doi:10.1016/S0040-4039(00)73889-5 
117. Albacker LA, Chaudhary V, Chang Y-J, Kim HY, Chuang YT, Pichavant M, 
et  al. Invariant natural killer T  cells recognize a fungal glycosphingolipid 
that can induce airway hyperreactivity. Nat Med (2013) 19(10):1297–304. 
doi:10.1038/nm.3321 
118. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural 
killer T cells by alpha-galactosylceramide rapidly induces the full maturation 
of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 
and CD8 T  cell immunity to a coadministered protein. J Exp Med (2003) 
198:267–79. doi:10.1084/jem.20030324 
119. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, et al. NKT cells 
enhance CD4+ and CD8+ T  cell responses to soluble antigen in  vivo 
through direct interaction with dendritic cells. J Immunol (2003) 171:5140–7. 
doi:10.4049/jimmunol.171.10.5140 
120. Haan den JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic 
cells cross-prime cytotoxic T cells in vivo. J Exp Med (2000) 192:1685–96. 
doi:10.1084/jem.192.12.1685 
121. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction 
of a CD8+ cytotoxic T  lymphocyte response by cross-priming requires 
cognate CD4+ T  cell help. J Exp Med (1997) 186:65–70. doi:10.1084/jem. 
186.1.65 
122. Aarntzen EH, de Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, 
et al. Targeting CD4(+) T-helper cells improves the induction of antitumor 
responses in dendritic cell-based vaccination. Cancer Res (2013) 73:19–29. 
doi:10.1158/0008-5472.CAN-12-1127 
123. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. 
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of 
CD4+ T cell-dendritic cell interaction. Nature (2006) 440:890–5. doi:10.1038/
nature04651 
124. Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer U, 
et al. Alternative cross-priming through CCL17-CCR4-mediated attraction 
of CTLs toward NKT  cell-licensed DCs. Nat Immunol (2010) 11:313–20. 
doi:10.1038/ni.1848 
125. Arora P, Venkataswamy MM, Baena A, Bricard G, Li Q, Veerapen N, 
et  al. A rapid fluorescence-based assay for classification of iNKT  cell 
activating glycolipids. J Am Chem Soc (2011) 133:5198–201. doi:10.1021/ 
ja200070u 
126. Im JS, Tapinos N, Chae G-T, Illarionov PA, Besra GS, DeVries GH, et  al. 
Expression of CD1d molecules by human schwann cells and potential 
interactions with immunoregulatory invariant NK T cells. J Immunol (2006) 
177:5226–35. doi:10.4049/jimmunol.177.8.5226 
127. Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, 
et  al. Distinct roles of dendritic cells and B  cells in Va14Ja18 natural 
T  cell activation in  vivo. J Immunol (2005) 174:4696–705. doi:10.4049/
jimmunol.174.8.4696 
128. Bai L, Constantinides MG, Thomas SY, Reboulet R, Meng F, Koentgen F, et al. 
Distinct APCs explain the cytokine bias of α-galactosylceramide variants 
in vivo. J Immunol (2012) 188:3053–61. doi:10.4049/jimmunol.1102414 
129. McCarthy C, Shepherd D, Fleire S, Stronge VS, Koch M, Illarionov PA, et al. 
The length of lipids bound to human CD1d molecules modulates the affinity 
of NKT cell TCR and the threshold of NKT cell activation. J Exp Med (2007) 
204:1131–44. doi:10.1084/jem.20062342 
130. van den Elzen P, Garg S, León L, Brigl M, Leadbetter EA, Gumperz JE, et al. 
Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 
(2005) 437:906–10. doi:10.1038/nature04001 
131. Freigang S, Zadorozhny V, McKinney MK, Krebs P, Herro R, Pawlak J, et al. 
Fatty acid amide hydrolase shapes NKT  cell responses by influencing the 
serum transport of lipid antigen in mice. J Clin Invest (2010) 120:1873–84. 
doi:10.1172/JCI40451 
132. Freigang S, Landais E, Zadorozhny V, Kain L, Yoshida K, Liu Y, et al. Scavenger 
receptors target glycolipids for natural killer T cell activation. J Clin Invest 
(2012) 122:3943–54. doi:10.1172/JCI62267 
133. Freigang S, Kain L, Teyton L. Transport and uptake of immunogenic lipids. 
Mol Immunol (2013) 55:179–81. doi:10.1016/j.molimm.2012.10.016 
134. Prigozy TI, Naidenko O, Qasba P, Elewaut D, Brossay L, Khurana A, et al. 
Glycolipid antigen processing for presentation by CD1d molecules. Science 
(2001) 291:664–7. doi:10.1126/science.291.5504.664 
135. Winau F, Schwierzeck V, Hurwitz R, Remmel N, Sieling PA, Modlin RL, et al. 
Saposin C is required for lipid presentation by human CD1b. Nat Immunol 
(2004) 5:169–74. doi:10.1038/ni1035 
136. la Salle de H, Mariotti S, Angenieux C, Gilleron M, Garcia-Alles L-F, Malm D, 
et al. Assistance of microbial glycolipid antigen processing by CD1e. Science 
(2005) 310:1321–4. doi:10.1126/science.1115301 
137. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoim-
mune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 
(2001) 413:531–4. doi:10.1038/35097097 
138. Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, et  al. 
Modulation of CD1d-restricted NKT cell responses by using N-acyl variants 
of alpha-galactosylceramides. Proc Natl Acad Sci U S A (2005) 102:3383–8. 
doi:10.1073/pnas.0407488102 
139. Im JS, Arora P, Bricard G, Molano A, Venkataswamy MM, Baine I, et  al. 
Kinetics and cellular site of glycolipid loading control the outcome of 
natural killer T  cell activation. Immunity (2009) 30:888–98. doi:10.1016/j.
immuni.2009.03.022 
140. Bai L, Sagiv Y, Liu Y, Freigang S, Yu KO, Teyton L, et al. Lysosomal recycling 
terminates CD1d-mediated presentation of short and polyunsaturated 
variants of the NKT cell lipid antigen alphaGalCer. Proc Natl Acad Sci U S A 
(2009) 106:10254–9. doi:10.1073/pnas.0901228106 
141. Buatois V, Baillet M, Bécart S, Mooney N, Leserman L, Machy P. MHC 
class II-peptide complexes in dendritic cell lipid microdomains initiate the 
CD4 Th1 phenotype. J Immunol (2003) 171:5812–9. doi:10.4049/jimmunol. 
171.11.5812 
142. Lee YJ, Wang H, Starrett GJ, Phuong V, Jameson SC, Hogquist KA. Tissue-
specific distribution of iNKT cells impacts their cytokine response. Immunity 
(2015) 43:566–78. doi:10.1016/j.immuni.2015.06.025 
143. Fujii S-I, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, et al. 
NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol (2013) 
4:409. doi:10.3389/fimmu.2013.00409 
144. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. 
Nat Rev Cancer (2012) 12:252–64. doi:10.1038/nrc3239 
145. Harada Y, Imataki O, Heike Y, Kawai H, Shimosaka A, Mori S, et  al. 
Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT  cells 
cultured in the absence of animal materials. J Immunother (2005) 28:314–21. 
doi:10.1097/01.cji.0000163593.66910.ad 
146. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I 
study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) 
in patients with solid tumors. Clin Cancer Res (2002) 8:3702–9. 
147. Parekh VV, Wilson MT, Olivares-Villagómez D, Singh AK, Wu L, Wang C-R, 
et  al. Glycolipid antigen induces long-term natural killer T  cell anergy in 
mice. J Clin Invest (2005) 115:2572–83. doi:10.1172/JCI24762 
148. Sullivan BA, Kronenberg M. Activation or anergy: NKT  cells are stunned 
by alpha-galactosylceramide. J Clin Invest (2005) 115:2328–9. doi:10.1172/
JCI26297 
149. Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, et al. PD-1/PD-L 
blockade prevents anergy induction and enhances the anti-tumor activities 
of glycolipid-activated invariant NKT cells. J Immunol (2009) 182:2816–26. 
doi:10.4049/jimmunol.0803648 
150. Sag D, Krause P, Hedrick CC, Kronenberg M, Wingender G. IL-10-producing 
NKT10 cells are a distinct regulatory invariant NKT cell subset. J Clin Invest 
(2014) 124:3725–40. doi:10.1172/JCI72308 
151. van der Vliet HJ, Molling JW, Nishi N, Masterson AJ, Kölgen W, Porcelli SA, 
et al. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy 
volunteers and cancer patients using alpha-galactosylceramide-loaded and 
environmentally instructed dendritic cells. Cancer Res (2003) 63:4101–6. 
13
Keller et al. DC–NKT Interactions
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 570
152. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting 
edge: inhibition of experimental tumor metastasis by dendritic cells pulsed 
with alpha-galactosylceramide. J Immunol (1999) 163:2387–91. 
153. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et  al. 
Sustained expansion of NKT cells and antigen-specific T cells after injection 
of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. 
J Exp Med (2005) 201:1503–17. doi:10.1084/jem.20042592 
154. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic 
activation of Valpha24+Vbeta11+ NKT cells in human subjects results in 
highly coordinated secondary activation of acquired and innate immunity. 
Blood (2004) 103:383–9. doi:10.1182/blood-2003-04-1155 
155. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, 
et  al. Combination therapy of in vitro-expanded natural killer T cells and 
alpha-galactosylceramide-pulsed antigen-presenting cells in patients 
with recurrent head and neck carcinoma. Cancer Sci (2009) 100:1092–8. 
doi:10.1111/j.1349-7006.2009.01135.x 
156. Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, 
et  al. Induction of NKT  cell-specific immune responses in cancer tissues 
after NKT  cell-targeted adoptive immunotherapy. Clin Immunol (2011) 
138:255–65. doi:10.1016/j.clim.2010.11.014 
157. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A 
phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured 
peripheral blood mononuclear cells in patients with advanced and recurrent 
non-small cell lung cancer. J Immunol (2009) 182:2492–501. doi:10.4049/
jimmunol.0800126 
158. Okita K, Motohashi S, Shinnakasu R, Nagato K, Yamasaki K, Sato Y, et al. A 
set of genes associated with the interferon-γ response of lung cancer patients 
undergoing α-galactosylceramide-pulsed dendritic cell therapy. Cancer Sci 
(2010) 101:2333–40. doi:10.1111/j.1349-7006.2010.01696.x 
159. Barral P, Polzella P, Bruckbauer A, van Rooijen N, Besra GS, Cerundolo V, 
et  al. CD169(+) macrophages present lipid antigens to mediate early 
activation of iNKT  cells in lymph nodes. Nat Immunol (2010) 11:303–12. 
doi:10.1038/ni.1853 
160. Macho-Fernandez E, Chang J, Fontaine J, Bialecki E, Rodriguez F, 
Werkmeister E, et  al. Activation of invariant natural killer T  lymphocytes 
in response to the α-galactosylceramide analogue KRN7000 encapsulated 
in PLGA-based nanoparticles and microparticles. Int J Pharm (2012) 
423:45–54. doi:10.1016/j.ijpharm.2011.04.068 
161. Nakamura T, Yamazaki D, Yamauchi J, Harashima H. The nanoparticulation by 
octaarginine-modified liposome improves α-galactosylceramide-mediated 
antitumor therapy via systemic administration. J Control Release (2013) 
171:216–24. doi:10.1016/j.jconrel.2013.07.004 
162. Fujii S, Goto A, Shimizu K. Antigen mRNA-transfected, allogeneic fibro-
blasts loaded with NKT-cell ligand confer antitumor immunity. Blood (2009) 
113:4262–72. doi:10.1182/blood-2008-08-176446 
163. Watarai H, Fujii S, Yamada D, Rybouchkin A, Sakata S, Nagata Y, et  al. 
Murine induced pluripotent stem cells can be derived from and differentiate 
into natural killer T  cells. J Clin Invest (2010) 120:2610–8. doi:10.1172/
JCI42027 
164. Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, et al. Invariant 
NKT cells with chimeric antigen receptor provide a novel platform for safe 
and effective cancer immunotherapy. Blood (2014) 124:2824–33. doi:10.1182/
blood-2013-11-541235 
165. Tian G, Courtney AN, Jena B, Heczey A, Liu D, Marinova E, et al. CD62L+ 
NKT cells have prolonged persistence and antitumor activity in vivo. J Clin 
Invest (2016) 126:2341–55. doi:10.1172/JCI83476 
166. Benlagha K, Wei DG, Veiga J, Teyton L, Bendelac A. Characterization of the 
early stages of thymic NKT cell development. J Exp Med (2005) 202:485–92. 
doi:10.1084/jem.20050456 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Keller, Freigang and Lünemann. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
